QURE Insider Trading

Insider Ownership Percentage: 4.74%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $1,042,573.95

uniQure Insider Trading History Chart

This chart shows the insider buying and selling history at uniQure by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$500k$0$500kTotal Insider BuyingTotal Insider Selling

uniQure Share Price & Price History

Current Price: $13.00
Price Change: Price Increase of +3.61 (38.45%)
As of 04/17/2025 05:00 PM ET

This chart shows the closing price history over time for QURE up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$13.00Closing price on 04/17/25:

SEC Filings (Institutional Ownership Changes) for uniQure (NASDAQ:QURE)

78.83% of uniQure stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at QURE by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$3.56Mbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100M-$50M$0$50M$100MTotal InflowsTotal Outflows
uniQure logo
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More on uniQure

Today's Range

Now: $13.00
Low: $12.54
High: $14.16

50 Day Range

MA: $11.89
Low: $8.34
High: $14.77

52 Week Range

Now: $13.00
Low: $3.73
High: $19.18

Volume

14,440,345 shs

Average Volume

1,738,888 shs

Market Capitalization

$703.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.42

Who are the company insiders with the largest holdings of uniQure?

uniQure's top insider shareholders include:
  1. Matthew C Kapusta (CEO)
  2. Christian Klemt (CFO)
  3. Ricardo Dolmetsch (Insider)
  4. Walid Abi-Saab (Insider)
  5. Pierre Caloz (COO)
  6. Jeannette Potts (Insider)
  7. Rachelle Suzanne Jacques (Director)
Learn More about top insider investors at uniQure.

Who are the major institutional investors of uniQure?

uniQure's top institutional investors include:
  1. Assenagon Asset Management S.A. — 0.62%
  2. Sanders Morris Harris LLC — 0.21%
Learn More about top institutional investors of uniQure stock.

Which institutional investors are buying uniQure stock?

In the previous quarter, QURE stock was acquired by institutional investors including:
  1. Assenagon Asset Management S.A.
  2. Sanders Morris Harris LLC